Median time to first skeletal-related events in the enzalutamide group was 311 months ( 95 % CI 295-not reached ) and 313 months ( 95 % CI 239-not reached ) in the placebo group ( HR 072 [ 95 % CI 061-084 ] ; p < 00001 ) .